drugset

drugset / Trial / NCT00125892

A Study of Duloxetine in the Treatment of Fibromyalgia

NCT00125892 ↗

Phase 3 Completed 320 enrolled Eli Lilly and Company Boehringer Ingelheim · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to evaluate duloxetine for the treatment of fibromyalgia syndrome patients.

Timeline

Start: 2005-07
Primary completion: —
Completion: 2007-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Duloxetine	Small molecule	—	—

Indications